Optimer Pharmaceuticals (NASDAQ: OPTR), AT&T Inc. (NYSE: T), NCI Inc. (NASDAQ: NCIT), Orbitz Worldwide, Inc. (NYSE: OWW), Cedar Fair, L.P. (NYSE: FUN) and Gilat Satellite Networks Ltd (NASDAQ: GILT) ratings and price targets.
Optimer Pharmaceuticals (OPTR) had its “buy” rating reiterated by Jefferies Group (NYSE:JEF). They have a price target of $17.00 on the firm.
AT&T Inc. (NYSE: T) is now covered by Deutsche Bank (NYSE:DB). They have a “hold” rating on the firm.
NCI Inc. (NCIT) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Orbitz Worldwide, Inc. (OWW) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Cedar Fair, L.P. (FUN) was upgraded by Zacks Investment Research from a “neutral” rating to an “outperform” rating.
Gilat Satellite Networks Ltd (GILT) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating.
Showing posts with label Optimer Pharmaceuticals. Show all posts
Showing posts with label Optimer Pharmaceuticals. Show all posts
Tuesday, January 10, 2012
Saturday, May 21, 2011
Ratings (VRSN) (CWT) (DGII) (OPTR) (ANTH) Weekend Recap
Ratings coverage on Verisign, Inc. (NASDAQ: VRSN), California Water Service Group (NYSE: CWT), Digi International Inc. (NASDAQ: DGII), Optimer Pharmaceuticals (NASDAQ: OPTR) and Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) was initiated by analysts recently.
Cowen initiated coverage on Verisign, Inc. (VRSN). They placed an “outperform” rating on the company.
Ladenburg Thalmann analysts initiated coverage on shares of California Water Service Group (CWT). They placed a “buy” rating and a price target of $42.00 on the company.
Feltl & Co. analysts initiated coverage on Digi International Inc. (DGII). They placed a “buy” rating and a $13.25 price target on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Leerink initiated coverage on Anthera Pharmaceuticals, Inc. (ANTH). They placed an “outperform” rating on the company.
Cowen initiated coverage on Verisign, Inc. (VRSN). They placed an “outperform” rating on the company.
Ladenburg Thalmann analysts initiated coverage on shares of California Water Service Group (CWT). They placed a “buy” rating and a price target of $42.00 on the company.
Feltl & Co. analysts initiated coverage on Digi International Inc. (DGII). They placed a “buy” rating and a $13.25 price target on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Leerink initiated coverage on Anthera Pharmaceuticals, Inc. (ANTH). They placed an “outperform” rating on the company.
Wednesday, May 18, 2011
Coverage on (ONCY) (OPTR) (SD) (PMCS) (POT) Initiated
Coverage on Oncolytics Biotech, Inc. (NASDAQ: ONCY), Optimer Pharmaceutic (NASDAQ: OPTR), SandRidge Energy Inc. (NYSE: SD), PMC-Sierra, Inc. (NASDAQ: PMCS) and Potash Corp (NYSE: POT) was initiated by analysts.
Robert W. Baird initiated coverage on SandRidge Energy Inc. (SD). They placed a “neutral” rating and a price target of $12.00 on the company.
Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc. (ONCY). They placed a “perform” rating on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Auriga initiated coverage on PMC-Sierra, Inc. (PMCS). They placed a “hold” rating and a price target of $8.00 on the company.
Macquarie initiated coverage on Potash Corp (POT). They placed an “outperform” rating and a price target of $62.00 on the company.
Robert W. Baird initiated coverage on SandRidge Energy Inc. (SD). They placed a “neutral” rating and a price target of $12.00 on the company.
Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc. (ONCY). They placed a “perform” rating on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Auriga initiated coverage on PMC-Sierra, Inc. (PMCS). They placed a “hold” rating and a price target of $8.00 on the company.
Macquarie initiated coverage on Potash Corp (POT). They placed an “outperform” rating and a price target of $62.00 on the company.
Tuesday, May 17, 2011
Coverage on (ONCY) (OPTR) (SD) (PMCS) (POT) Initiated
Coverage on Oncolytics Biotech, Inc. (NASDAQ: ONCY), Optimer Pharmaceutic (NASDAQ: OPTR), SandRidge Energy Inc. (NYSE: SD), PMC-Sierra, Inc. (NASDAQ: PMCS) and Potash Corp (NYSE: POT) was initiated by analysts.
Robert W. Baird initiated coverage on SandRidge Energy Inc. (SD). They placed a “neutral” rating and a price target of $12.00 on the company.
Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc. (ONCY). They placed a “perform” rating on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Auriga initiated coverage on PMC-Sierra, Inc. (PMCS). They placed a “hold” rating and a price target of $8.00 on the company.
Macquarie initiated coverage on Potash Corp (POT). They placed an “outperform” rating and a price target of $62.00 on the company.
Robert W. Baird initiated coverage on SandRidge Energy Inc. (SD). They placed a “neutral” rating and a price target of $12.00 on the company.
Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc. (ONCY). They placed a “perform” rating on the company.
ThinkEquity initiated coverage on Optimer Pharmaceutic (OPTR). They placed a “buy” rating and a price target of $18.00 on the company.
Auriga initiated coverage on PMC-Sierra, Inc. (PMCS). They placed a “hold” rating and a price target of $8.00 on the company.
Macquarie initiated coverage on Potash Corp (POT). They placed an “outperform” rating and a price target of $62.00 on the company.
Friday, January 7, 2011
Optimer (NASDAQ:OPTR) Should Get Fidaxomicin Approval in U.S, Europe
Applications for fidaxomicin were submitted by Optimer (NASDAQ:OPTR) to the appropriate regulatory agencies in 2010, and Needham says they have a good chance of being approved after Phase 3 results.
Needham noted, "Optimer submitted both European and U.S. regulatory applications for fidaxomicin (FDX) in 2010. We remain favorably inclined based on a successful Phase 3 program and anticipate approval in both regions in 2011. We believe the stock is undervalued (~$390MM EV), given low regulatory risk and proximity to commercialization."
Needham & Company maintains a "Buy" on Optimer Pharmaceuticals, which closed Thursday at $11.41, down $0.07, or 0.61 percent. They have a price target on them of $19.
Needham noted, "Optimer submitted both European and U.S. regulatory applications for fidaxomicin (FDX) in 2010. We remain favorably inclined based on a successful Phase 3 program and anticipate approval in both regions in 2011. We believe the stock is undervalued (~$390MM EV), given low regulatory risk and proximity to commercialization."
Needham & Company maintains a "Buy" on Optimer Pharmaceuticals, which closed Thursday at $11.41, down $0.07, or 0.61 percent. They have a price target on them of $19.
Monday, November 22, 2010
Optimer Pharmaceuticals' (NASDAQ:OPTR) Fidaxomicin Should Drive Stock in 2011
With the expected approval of their lead drug fidaxomicin expected in 2011, Optimer Pharmaceuticals (NASDAQ:OPTR) should get a big boost next year after a U.S. and European Union go ahead.
Canaccord said, "We continue to believe Optimer’s lead drug, fidaxomicin (fidaxo) for the treatment of Clostridium difficile infection (CDI), offers a strong value proposition. We believe that approval of the drug in the US and EU next year will drive significant upside in the stock."
Optimer closed at $9.48 Friday, gaining $0.38, or 4.18 percent. Canaccord has a hefty price target on them of $18, and maintains their "Buy" rating on them.
Canaccord said, "We continue to believe Optimer’s lead drug, fidaxomicin (fidaxo) for the treatment of Clostridium difficile infection (CDI), offers a strong value proposition. We believe that approval of the drug in the US and EU next year will drive significant upside in the stock."
Optimer closed at $9.48 Friday, gaining $0.38, or 4.18 percent. Canaccord has a hefty price target on them of $18, and maintains their "Buy" rating on them.
Subscribe to:
Posts (Atom)